


WHAT IS CLAIMED IS:

1. A compound of formula (I)



(I)

where

X is  or ;

E is NH or CH_2;

W is CR^{10};

Y is CR^{11};

V is CR^{12};

 is C_3-C_8 cycloalkyl;

R^1 is C_1-C_{10} alkyl optionally substituted with halo or phenyl wherein said phenyl may be optionally substituted with halo;


R^2 is COOH, heteroaryl or $–CONHSO_2R^{14}$;

R^3 is H, C_1-C_{10} alkyl or halo;

R^4 is H, C_1-C_{10} alkyl, or halo;

R^6 is H;

R^7 and R^8 are independently selected from the group consisting of C_1-C_{10} alkyl optionally substituted with halo or phenyl, wherein said phenyl may be optionally substituted with halo, C_1-C_{10} alkoxy, C_1-C_{10}-alkoxy-C_1-C_{10}-alkyl, C_3-C_8 cycloalkyl, aryl optionally substituted with halo;

R^9 is aryl, C_1-C_{10} alkylaryl, C_3-C_8 cycloalkylaryl, C_1-C_{10} alkoxyaryl, C_1-C_{10} alkyl heteroaryl, heteroaryl, or ;

wherein R^9 may be substituted with at least one alkyl, halo, alkoxy, CN or haloalkyloxy;

R^{10} is H or halo;


R^{11} is H or halo; and


R^{12} is H, C_1-C_{10} alkyl, or C_2-C_{10} alkenyl;

R^{14} is CF_3, C_3-C_8 cycloalkyl or C_1-C_{10} alkyl;

and/or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 wherein




is 

;

X is NR^7R^8;

E is NH;

R^2 is COOH, 

or $-CONHSO_2R^{14}$;

R^3 is H or C_1-C_6 alkyl;

R^4 is H, C_1-C_6 alkyl, or halo;

R^6 is H;

R^7 and R^8 are independently selected from C_1-C_6 alkyl, C_1-C_6 alkoxy, C_3-C_8 cycloalkyl, or C_1-C_6-alkoxy-C_1-C_6-alkyl;

R^{10} is H;


R^{11} is halo or H; and

R^{12} is H;

R^{14} is CF_3, C_3-C_6 cycloalkyl or C_1-C_6 alkyl;


and/or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof.

3. The compound according to Claim 1 wherein



is ;

E is NH;



X is ;

R^2 is COOH;


R^3, R^4, R^5 and R^6 are H;

R^7 and R^8 are independently selected from C_1-C_{10} alkyl;


R^9 is C_1-C_{10} alkylaryl;

and/or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof.

4. The compound according to Claim 3 wherein

R^7 and R^8 are each 


; and


R^9 is 

;

and/or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof.

5. The compound according to Claim 1 wherein




is 

;

X is OR^1;

E is NH;

R^2 is COOH,  or $-CONHSO_2R^{14}$;

R^3, R^4, R^5 and R^6 are H;

R^1 is aryl-C_1-C_6-alkyl, or C_1-C_6 alkyl wherein R^1 may be optionally substituted with halo;



R^9 is aryl or C_1-C_6 alkylaryl wherein R^9 may be optionally substituted with at least one alkyl, halo, alkoxy, CN or haloalkyloxy;

R^{12} is H, C_1-C_6 alkyl, C_2-C_6 alkenyl, or halo;

and/or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof.

6. The compound according to Claim 1 wherein

E is CH_2;

 is ;

X is $-NR^7R^8$;


R^2 is COOH; and



R^7 and R^8 are independently selected from C_1-C_6 alkyl;

and/or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof.

7. The compound according to Claim 6 wherein

R^2 is COOH;

R^7 and R^8 are each ;

R^9 is  or ;

and/or a stereoisomer, tautomer or a pharmaceutically acceptable salt thereof.

8. The compound according to Claim 1 wherein the IC_{50} in the HEK Human IDO-1 assay is < 10 nM.

9. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.

10. A method of inhibiting activity of indoleamine 2,3-dioxygenase comprising contacting said indoleamine 2,3-dioxygenase with a compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the contacting of said indoleamine 2,3-dioxygenase with the compound, or the pharmaceutically acceptable salt thereof is performed *in vitro*.

11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:

(1R,2S)-2-(4-(cyclohexyl(4,4,4-trifluoro-2-methylbutyl)amino)-3-(2-(ptolyl) acetamido)phenyl)cyclopropanecarboxylic acid;

(1S,2R)-2-(4-(cyclohexyl(4,4,4-trifluoro-2-methylbutyl)amino)-3-(2-(ptolyl) acetamido)phenyl)cyclopropanecarboxylic acid, mixture of diastereomers;

2-(4-(diisobutylamino)-3-(3-o-tolylureido)phenyl) cyclopropanecarboxylic acid;

(1S,2R)-2-(4-(diisobutylamino)-3-(3-(p-tolyl)ureido)phenyl)-N-(methylsulfonyl)cyclopropanecarboxamide;

(1S,2R)-N-(cyclopropylsulfonyl)-2-(4-(diisobutylamino)-3-(3-(ptolyl)ureido)phenyl)cyclopropanecarboxamide;

(1S,2R)-2-(4-((S)-1-phenylpropoxy)-3-(3-(p tolyl)ureido)phenyl)cyclopropanecarboxylic acid;

(1R,2S)-2-(4-((R)-1-phenylpropoxy)-3-(3-(p-tolyl)ureido) phenyl)cyclopropanecarboxylic acid;

(1R,2S)-2-(4-(cyclohexyl(isobutyl)amino)-3-(3-(3-methylisoxazol-5-yl)ureido)phenyl)cyclopropanecarboxylic acid; and

(1S,2R)-2-(4-(diisobutylamino)-3-(3-ptolylureido) phenyl)cyclopentanecarboxylic acid.